New Prognostic and Predictive Markers in Cancer Progression

Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions suc...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2021
Language:English
Physical Description:1 electronic resource (294 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 04583nam-a2201225z--4500
001 993546334004498
005 20231214133144.0
006 m o d
007 cr|mn|---annan
008 202105s2021 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000045439 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/68373 
035 |a (EXLCZ)995400000000045439 
041 0 |a eng 
100 1 |a Costantini, Susan  |4 edt 
245 1 0 |a New Prognostic and Predictive Markers in Cancer Progression 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2021 
300 |a 1 electronic resource (294 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a MSI2 
653 |a OSCC 
653 |a oral cancer 
653 |a musashi 2 
653 |a prognosis 
653 |a N-cadherin 
653 |a EMT 
653 |a breast cancer 
653 |a new metastasis 
653 |a eribulin 
653 |a blood 
653 |a biomarker 
653 |a bladder cancer 
653 |a immune checkpoint inhibitor 
653 |a CD8+ T effector cells 
653 |a microRNA 
653 |a biomarkers 
653 |a head and neck cancer 
653 |a laryngeal cancer 
653 |a prediction 
653 |a metastasis 
653 |a lifestyle habit 
653 |a chemo-/radio resistance 
653 |a therapeutic target 
653 |a AKT 
653 |a AR 
653 |a castration-resistant prostate cancer (CRPC) 
653 |a MAPK 
653 |a mTOR 
653 |a PI3K 
653 |a prostate cancer 
653 |a therapeutic resistance 
653 |a WNT 
653 |a miRNA 
653 |a melanoma 
653 |a melanoma resistance to MAPK/MEK inhibitors 
653 |a resistance to immune checkpoint inhibitors 
653 |a TNBC 
653 |a BRCA1/2 
653 |a HRR 
653 |a PDL1 
653 |a TILs 
653 |a PI3KCA 
653 |a PTEN 
653 |a CTCs 
653 |a CSC 
653 |a pancreatic cancer 
653 |a K-RAS oncogene 
653 |a oncogene dependency 
653 |a targeted therapies 
653 |a genomic mutations 
653 |a transcriptomics 
653 |a metabolomics 
653 |a selenoproteins 
653 |a cancer 
653 |a HUB nodes 
653 |a major histocompatibility complex (MHC) 
653 |a human leukocyte antigen (HLA) 
653 |a antigen processing machinery (APM) molecules 
653 |a carcinogenesis 
653 |a tumor predisposition 
653 |a cancer immunotherapy 
653 |a pheochromocytoma 
653 |a paraganglioma 
653 |a head and neck neoplasms 
653 |a head and neck tumors 
653 |a genetic syndromes 
653 |a mutations 
653 |a hyperglycemia 
653 |a cardioncology 
653 |a nivolumab 
653 |a cytokines 
653 |a cardiotoxicity 
653 |a acetyltransferase 
653 |a cancer prognosis 
653 |a NAA10 
776 |z 3-03943-977-4 
776 |z 3-03943-978-2 
700 1 |a Budillon, Alfredo  |4 edt 
700 1 |a Costantini, Susan  |4 oth 
700 1 |a Budillon, Alfredo  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:44:29 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338232780004498&Force_direct=true  |Z 5338232780004498  |b Available  |8 5338232780004498